Background: Covered self-expanding metal stents (SEMS) are widely used for the management of malignant biliary duct strictures. Recently, randomized studies have compared bare and covered biliary SEMS. A new family of biliary SEMS is being introduced, the Fully Covered, Partially Covered, and Uncovered WallFlex biliary SEMS (Boston Scientific, Natick, MA, USA). Methods: The new WallFlex™ Biliary Partially Covered Stent is indicated for palliative treatment of bile duct obstructions caused by malignant neoplasms, and has not yet received regulatory clearance in the United States. Enrollment in a 70 patient prospective multi-center trial is complete and follow-up is ongoing. Primary endpoint is adequate palliation defined as absence of recurrent biliary obstruction until 6 months or death. Secondary measures include evaluation of success of stent placement, complications, and seven common biliary obstructive symptoms assessed at baseline and at each follow-up visit. One consented patient did not receive a stent because of failure to cannulate. Results: Patients are 52% male, mean age 69 (range 34-92). Malignancy was carcinoma of the pancreas in 67% (45), bile duct in 15% (10), gallbladder in 4% (3), ampulla in 4% (3), colon in 3% (2), other in 6% (4), and unreported in 3% (2). 67 patients received 1 stent and 2 patients received 2 stents. 55% of patients received the SEMS de novo and 45% in exchange of a previously implanted plastic stent. Mean procedure duration was 27 minutes (range 5-95). Technical success at stent placement was 94% (65/69). To date 3 patients died due to underlying disease, 1 patient had a stent occlusion due to tumor overgrowth on day 36 managed by placement of a second SEMS inside the Wallflex stent, 8 patients followed to 3 months required no re-intervention, and there were no migrations. From baseline to 1 month the mean number of reported obstructive symptoms improved from 3 to 0.5 and total bilirubin levels reduced on average by 81%. At 1 month 63% of patients were free of all obstructive symptoms. Thus far there were 4 device and/or procedure related complications in 3 patients: 1 cholangitis, 1 acute cholecystitis managed by percutaneous cholecystotomy, and in one patient 1 perforation of the bulbus at stent placement and 1 pancreatitis. Conclusions: This new self-expandable partially covered nitinol stent has proven to be easily implantable, safe, and effective in the short-term palliation of symptoms of biliary obstruction secondary to unresectable or inoperable cancer. Further follow-up is necessary and ongoing to assess long-term adequate palliation by this stent.